BiotechTube

SCH 530348

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Arterial Obstructive Diseases

Conditions

Arterial Obstructive Diseases, Coronary Disease

Trial Timeline

Aug 30, 2005 → Jan 28, 2007

NCT ID
NCT00132912

About SCH 530348

SCH 530348 is a phase 2 stage product being developed by Merck for Arterial Obstructive Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT00132912. Target conditions include Arterial Obstructive Diseases, Coronary Disease.

What happened to similar drugs?

20 of 20 similar drugs in Arterial Obstructive Diseases were approved

Approved (20) Terminated (7) Active (0)
✅Sarpogrelate SR + SarpogrelateYuhanApproved
✅tadalafil and ambrisentan upfront combination therapyEli LillyApproved
✅RiociguatMerckApproved
✅SotaterceptMerckApproved
✅Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months.AmgenApproved
✅Ambrisentan + Placebo + Sildenafil + TadalafilGilead SciencesApproved
✅AmbrisentanGilead SciencesApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00132912Phase 2Completed

Competing Products

20 competing products in Arterial Obstructive Diseases

See all competitors
ProductCompanyStageHype Score
CS1 AdministrationCereno ScientificPhase 2
29
CS1Cereno ScientificPre-clinical
24
Dose A KER-012 + Dose B KER-012 + Dose C KER-012 + Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeksKeros TherapeuticsPhase 2
25
Satralizumab (Genetical Recombination)Chugai PharmaceuticalPhase 2
39
Sarpogrelate SR + SarpogrelateYuhanApproved
43
edoxaban + Clopidogrel + AspirinDaiichi SankyoPhase 2
35
tadalafil and ambrisentan upfront combination therapyEli LillyApproved
43
Tadalafil- Tablet or Oral suspensionEli LillyPhase 1/2
32
tadalafilEli LillyPre-clinical
26
Orforglipron + PlaceboEli LillyPhase 3
47
NS-863 Low Dose + NS-863 High Dose + NS-863 PlaceboNippon ShinyakuPhase 2
42
OlaparibAstraZenecaPhase 1/2
24
MK-8892 + Placebo for MK-8892MerckPhase 1
29
RiociguatMerckApproved
35
SotaterceptMerckApproved
50
Sotatercept + Background PAH TherapyMerckPhase 2
35
Sotatercept + Placebo + Background PAH TherapyMerckPhase 3
40
SotaterceptMerckPhase 3
40
SotaterceptMerckPhase 3
40
Frespaciguat + PlaceboMerckPhase 1
29